Effects of three different testosterone formulations in female-to-male transsexual persons

Journal of Sexual Medicine

Volumn 11, Issue 12, 2014, Pages 3002-3011

  Pelusi, Carla ^a   Costantino, Antonietta ^a   Martelli, Valentina ^a   Lambertini, Martina ^a   Bazzocchi, Alberto ^a,b   Ponti, Federico ^a   Battista, Giuseppe ^a   Venturoli, Stefano ^a   Meriggiola, Maria C ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Body composition; Bone; Gender dysphoria; Life satisfaction; Testosterone; Transsexuals

Indexed keywords

FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; INSULIN; LACTATE DEHYDROGENASE; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; DRUG COMBINATION; GEL; SEX HORMONE;

ADULT; AMENORRHEA; ARTICLE; BODY COMPOSITION; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG SAFETY; EVENING DOSAGE; FAT MASS; FEMALE; FEMALE TO MALE TRANSGENDER; GEL; HUMAN; INSULIN SENSITIVITY; LEAN BODY WEIGHT; LIPOPROTEIN BLOOD LEVEL; PARTIAL THROMBOPLASTIN TIME; PATIENT SATISFACTION; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; VIRILIZATION; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING; BODY WEIGHT; BONE DENSITY; DRUG COMBINATION; DRUG EFFECTS; LIPID METABOLISM; MALE; TRANSSEXUALISM; TREATMENT OUTCOME;

ADULT; BLOOD COAGULATION; BODY COMPOSITION; BODY WEIGHT; BONE DENSITY; DRUG COMBINATIONS; FEMALE; GELS; GONADAL STEROID HORMONES; HUMANS; INSULIN; LIPID METABOLISM; MALE; PATIENT SATISFACTION; TESTOSTERONE; TRANSSEXUALISM; TREATMENT OUTCOME;

EID: 84913606242     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12698     Document Type: Article

References (39)

1. Hembree WC, Cohen-Kettenis P, Delemarre-Van de Waal HA, Gooren LJ, Meyer WJ III, Spack NP, Tangpricha V, Montori VM. Endocrine treatment of transsexual persons: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009;94:3132-3154.
2. Meriggiola MC, Jannini EA, Lenzi A, Maggi M, Manieri C. Endocrine treatment of transsexual persons: An Endocrine Society Clinical Practice Guideline: Commentary from a European perspective. Eur J Endocrinol 2010;162:831-833.
3. Gooren LJ. Clinical practice. Care of transsexual persons. N Engl J Med 2011;364:1251-1257.
4. Meriggiola MC, Berra M. Safety of hormonal treatment in transgenders. Curr Opin Endocrinol Diabetes Obes 2013;20:565-569.
5. Nieschlag E, Behre HM, Bouchard P, Corrales JJ, Jones TH, Stalla GK, Webb SM, Wu FC. Testosterone replacement therapy: Current trends and future directions. Hum Reprod Update 2004;10:409-419.
6. Gooren LJ. Hormone treatment of the adult transsexual patient. Horm Res 2005;64:31-36.
7. Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: Extensive personal experience. J Clin Endocrinol Metab 2008;93:19-25.
8. Traish AM, Gooren LJ. Safety of physiological testosterone therapy in women: Lessons from female-to-male transsexuals (FMT) treated with pharmacological testosterone therapy. J Sex Med 2010;7:3758-3764.
9. Jacobeit JW, Gooren LJ, Schulte HM. Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. Eur J Endocrinol 2009;161:795-798.
10. Meriggiola MC, Armillotta F, Costantino A, Altieri P, Saad F, Kalhorn T, Perrone AM, Ghi T, Pelusi C, Pelusi G. Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals. J Sex Med 2008;5:2442-2453.
11. Gooren LJ, Giltay EJ. Review of studies of androgen treatment of female-to-male transsexuals: Effects and risks of administration of androgens to females. J Sex Med 2008;5:765-776.
12. Berra M, Armillotta F, D'Emidio L, Costantino A, Martorana G, Pelusi G, Meriggiola MC. Testosterone decreases adiponectin levels in female to male transsexuals. Asian J Androl 2006;8:725-729.
13. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: A meta-analysis. Clin Endocrinol (Oxf) 2005;63:280-293.
14. Corona G, Rastrelli G, Forti G, Maggi M. Update in testosterone therapy for men. J Sex Med 2011;8:639-654.
15. Saad F, Kamischke A, Yassin A, Zitzmann M, Schubert M, Jockenhel F, Behre HM, Gooren L, Nieschlag E. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate. Asian J Androl 2007;9:291-297.
16. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: A meta-analysis. Am J Med 2001;111:261-269.
17. Mueller A, Haeberle L, Zollver H, Claassen T, Kronawitter D, Oppelt PG, Cupisti S, Beckmann MW, Dittrich R. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals. J Sex Med 2010;7:3190-3198.
18. Elbers JM, Giltay EJ, Teerlink T, Scheffer PG, Asscheman H, Seidell JC, Gooren LJ. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Oxf) 2003;58:562-571.
19. Asscheman H. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2011;164:635-642.
20. Lohman TG. Advances in body composition assessment. Current issues in exercise science series (monograph 3). Champaign, IL: Human Kinetics; 1992.
21. Pelusi C, Costantino A, Cerpolini S, Pelusi G, Meriggiola MC, Pasquali R. A placebo-controlled, randomized clinical trial using testosterone undecanoate with injectable norethisterone enanthate: Effect on anthropometric, metabolic and biochemical parameters. Int J Androl 2011;34:548-555.
22. Vermeulen A, Verdonck L, Kaufmann JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. JCEM 1999;84:3666-3672.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
24. Brokelman RBG, Haverkamp D, Van Loon C, Hol A, Van Kampen A, Veth R. The validation of the visual analogue scale for patient satisfaction after total hip arthroplasty. Eur Orthop Traumatol 2012;3:101-105.
25. Jacobeit JW, Gooren LJ, Schulte HM. Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. J Sex Med 2007;4:1479-1484.
26. Polderman KH, Gooren LJ, Asscheman H, Bakker A, Heine RJ. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 1994;79:265-271.
27. Mueller A, Kiesewetter F, Binder H, Beckmann MW, Dittrich R. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. J Clin Endocrinol Metab 2007;92:3470-3475.
28. Van Caenegem E, Wierckx K, Taes Y, Dedecker D, Van de Peer F, Toye K, Kaufman JM, T'Sjoen G. Bone mass, bone geometry, and body composition in female-to-male transsexual persons after long-term cross-sex hormonal therapy. J Clin Endocrinol Metab 2012;97:2503-2511.
29. Wierckx K, Van de Peer F, Verhaeghe E, Dedecker D, Van Caenegem E, Toye K, Kaufman JM, T'Sjoen G. Short- and long-term clinical skin effects of testosterone treatment in trans men. J Sex Med 2014;1:222-229.
30. Elbers JMH, Asscheman H, Seidell JC, Gooren LJG. Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. Am J Physiol 1999;276:E317-325.
31. Cupisti S, Giltay EJ, Gooren LJ, Kronawitter D, Oppelt PG, Beckmann MW, Dittrich R, Mueller A. The impact of testosterone administration to female-to-male transsexuals on insulin resistance and lipid parameters compared with women with polycystic ovary syndrome. Fertil Steril 2010;94:2647-2653.
32. Bachman E, Feng R, Travison T, Li M, Olbina G, Ostland V, Ulloor J, Zhang A, Basaria S, Ganz T, Westerman M, Bhasin S. Testosterone suppresses hepcidin in men: A potential mechanism for testosterone-induced erythrocytosis. J Clin Endocrinol Metab 2010;95:4743-4747.
33. Glueck CJ, Goldenberg N, Budhani S, Lotner D, Abuchaibe C, Gowda M, Nayar T, Khan N, Wang P. Thrombotic events after starting exogenous testosterone in men with previously undiagnosed familiar thrombophilia. Transl Res 2011;8:225-234.
34. Glueck CJ, Richardson-Royer C, Schultz R, Burger T, Bowe D, Padda J, Wang P. Testosterone therapy, thrombophilia-hypofibrinolysis, and hospitalization for deep venous thrombosis-pulmonary embolus: An exploratory, hypothesis-generating study. Clin Appl Thromb Hemost 2014;3:244-249.
35. Glueck CJ, Richardson-Royer C, Schultz R, Burger T, Labitue F, Riaz MK, Padda J, Bowe D, Goldenberg N, Wang P. Testosterone, thrombophilia, and thrombosis. Clin Appl Thromb Hemost 2014;1:22-30.
36. Costantino A, Cerpolini S, Alvisi S, Morselli PG, Venturoli S, Meriggiola MC. A prospective study on sexual function and mood in female-to-male transsexuals during testosterone administration and after sex reassignment surgery. J Sex Marital Ther 2013;39:321-335.
37. Murad MH, Elamin MB, Garcia MZ, Mullan RJ, Murad A, Erwin PJ, Montori VM. Hormonal therapy and sex reassignment: A systematic review and meta-analysis of quality of life and psychosocial outcomes. Clin Endocrinol 2010;72:214-231.
38. Fisher AD, Castellini G, Bandini E, Casale H, Fanni E, Benni L, Ferruccio N, Meriggiola MC, Manieri C, Gualerzi A, Jannini E, Oppo A, Ricca V, Maggi M, Rellini AH. Cross-sex hormonal treatment and body uneasiness in individuals with gender dysphoria. J Sex Med 2014;11:709-719.
39. Gorin-Lazard A, Baumstarck K, Boyer L, Maquigneau A, Penochet JC, Pringuey D, Albarel F, Morange I, Bonierbale M, Lançon C, Auquier P. Hormonal therapy is associated with better self-esteem, mood, and quality of life in transsexuals. J Nerv Ment Dis 2013;201:996-1000.